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ABSTRACT
Lipids are important cellular components which can be significantly altered 
in a range of disease states including prostate cancer. Here, a unique systematic 
approach has been used to define lipid profiles of prostate cancer cell lines, using 
quantitative mass spectrometry (LC-ESI-MS/MS), FTIR spectroscopy and fluorescent 
microscopy. All three approaches identified significant difference in the lipid profiles of 
the three prostate cancer cell lines (DU145, LNCaP and 22RV1) and one non-malignant 
cell line (PNT1a). Specific lipid classes and species, such as phospholipids (e.g., 
phosphatidylethanolamine 18:1/16:0 and 18:1/18:1) and cholesteryl esters, detected 
by LC-ESI-MS/MS, allowed statistical separation of all four prostate cell lines. Lipid 
mapping by FTIR revealed that variations in these lipid classes could also be detected 
at a single cell level, however further investigation into this approach would be needed 
to generate large enough data sets for quantitation. Visualisation by fluorescence 
microscopy showed striking variations that could be observed in lipid staining patterns 
between cell lines allowing visual separation of cell lines. In particular, polar lipid 
staining by a fluorescent marker was observed to increase significantly in prostate 
cancer lines cells, when compared to PNT1a cells, which was consistent with lipid 
quantitation by LC-ESI-MS/MS and FTIR spectroscopy. Thus, multiple technologies can 
be employed to either quantify or visualise changes in lipid composition, and moreover 
specific lipid profiles could be used to detect and phenotype prostate cancer cells.
INTRODUCTION
A hallmark of cancer cells is their metabolic 
reprogramming, which enables them to rapidly proliferate, 
migrate and alter their microenvironment to facilitate 
metastasis. Characteristics of metabolic alterations in 
cancer cells include significant increases in glucose 
and glutamine consumption [1], and alterations in lipid 
transport and utilisation [2]. Unlike many other cancer 
cells, prostate cancer cells exhibit a major reliance upon 
the uptake and metabolism of fatty acids, when compared 
to glucose uptake and glycolysis [3]. Overexpression of 
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fatty acid synthase (FAS) is associated with an increased 
risk of mortality from prostate cancer, which rises further 
when combined with a loss of the phosphatase and tensin 
homolog (PTEN) tumour suppressor gene [4]. The loss or 
inactivation of PTEN induces an upregulation of FAS that 
is mediated via the activation of phosphoinositide 3-kinase 
(PI3K)/AKT pathway [5]. Furthermore, concomitant 
activation of PI3K/AKT and MAPK pathways increases 
sterol regulatory element-binding protein (SREBP)-
dependent lipogenesis [6]; compounding the downstream 
effects of androgen-regulated (AR) metabolism [7], lipid 
composition and architecture of cellular membranes. The 
altered synthesis and metabolism of lipids in prostate 
cancer cells and changes to lipid profiles is therefore being 
recognised as a key feature of the pathogenesis [8, 9].
Altered lipid signalling pathways and lipid signatures 
may offer insights into the metabolic reprograming that 
occurs in prostate cancer cells and disease progression. 
Thus, the quantitation and visualisation of the cellular 
lipids may aid in the understanding of prostate cancer 
pathogenesis. Lipidomics of prostate cancer using mass 
spectrometry (MS) has already shown that cholesteryl 
esters (CE) are present at higher concentrations than 
in a normal prostate tissue [10]. Moreover, significant 
alterations have been observed in prostate cancer patient 
plasma concentrations of phosphoethanolamine (PE), 
ether-linked PE, phosphatidylinositol, ether-linked 
phosphatidylcholine (PC), sphingomyelin (SM) and 
ceramide [8, 11]. Alternative technologies, such as 
Fourier transform infrared spectroscopy (FTIR), have 
also been applied to identify changes in prostate cancer 
tissues in an effort to identify biomarkers for diagnosis 
[12, 13]. Changes in lipid features could be identified in 
prostate cancer patient samples and were correlated with 
patient grading [12]. Although this approach is only able 
to identify lipids down to a class level, FTIR does have 
a number of advantages over MS, as it does not require 
internal standards, can be applied to intact cells or tissue 
samples for lipid profiling and can provide spatial as well 
as quantitative information [14]. Fluorescence microscopy 
is another approach which can provide important spatial 
information about lipids with minimal requirements 
for sample preparation. To date this approach has been 
limited by the number of fluorescent stains available for 
the detection of endogenous lipids. Several lipophilic 
dyes such as Oil Red O, Nile Red and BODIPY® 493/503 
have been available for some years; however, these dyes 
primarily localise with neutral lipids, such as CE and 
triacylglycerides (TAG), and not with polar lipids, which 
have been implicated in prostate cancer pathogenesis 
from studies on plasma lipodomics. The availability of 
next generation dyes such as, the luminescent Rhenium(I) 
complex, ReZolve-L1TM, which has been shown to 
localise in areas of high polar lipid content (e.g. in 
close association with SM, PE and PC) in live and fixed 
adipocytes [15], warrant the investigation of fluorescence 
imaging as a potential method in lipid profiling.
Although lipid signatures have been identified in 
primary tumour tissues and plasma samples from prostate 
cancer patients, there has yet to be a study evaluating lipid 
profiles within cell models of prostate cancer. Therefore, 
in this study several approaches were utilized including 
liquid chromatography-electrospray ionization-tandem 
mass spectrometry (LC-ESI-MS/MS), FTIR spectroscopy 
and fluorescence imaging to characterise lipid profiles in 
a number of prostate cells lines. Three prostate cancer cell 
lines DU145, 22RV1 and LNCaP and one non-malignant 
PNT1a cells were used to compare lipid profiles. DU145 
represents late stage prostate cancer with moderate 
metastatic potential [16], and is neither hormone-sensitive 
nor expresses PSA. The cell lines, 22RV1 and LNCaP 
more closely mimic aspects of the more common clinical 
disease, as they are androgen-responsive and express PSA 
[17]. The lipid profiles obtained indicated that these cell 
lines provide comparable lipid changes to those reported 
in patient samples and further demonstrate that multiple 
approaches can be used to provide insight into lipid 
content of cells.
RESULTS
LC-ESI-MS/MS was performed on total lipid 
extracts prepared from non-malignant PNT1a and three 
prostate cancer cell lines, DU145, 22RV1 and LNCaP. 
A total of 53 lipid species were quantified, including 30 
detected in positive-ion mode and 23 detected in negative-
ion mode; covering six different lipid classes, including 
CE, SM, free cholesterol (FC) and PC in positive-ion 
mode, and PE and gangliosides (GM) in negative-ion 
mode (Supplementary Table 1). PE showed increased 
levels in all three prostate cancer cell lines, when 
compared to non-malignant PNT1a cells (Figure 1a). An 
increase in SM and PC was detected in 22RV1 and LNCaP 
cells, when compared to PNT1a cells, while DU145 cells 
displayed significantly reduced amounts of these lipids 
(Figure 1a). The concentration of CE, FC and GM varied 
between cell lines, and there was no consistent change in 
these lipids that distinguished prostate cancer derived cell 
lines from non-malignant PNT1a cells (Figure 1a).
To further interrogate the difference in lipid profiles 
between the four cell lines under investigation, principal 
component analysis (PCA) was performed on all 53 lipid 
species. In this analysis, prostate cancer cells lines were 
visually separated from one another and from the non-
malignant cell line PNT1a along the PC-1 and PC-2 axes, 
which accounted for 78% and 16% of the overall variance 
in the data, respectively (Figure 1b). The scores plot 
showed distinct separation of each prostate cell line along 
PC-1, with DU145 cells exhibiting the most negative 
scores and LNCaP cells exhibiting the most positive 
scores. PNT1a and 22RV1 cells were also observed to 
separate along the PC-1 axis, but their location close to 
the centre indicates less variability exists between these 
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cell lines (Figure 1b). The separation of PNT1a from 
LNCaP cells was much greater than for either 22RV1 
or DU145 prostate cancer cells. The PC-1 and PC-2 
loadings plot suggested that 11 lipid species accounted 
for the principal differences between the four cell lines; 
FC, CE (18:1), PE (18:1/16:0), PE (18:1/18:1), PC (32:1), 
PC (34:1), PC (36:2), SM (18:1/20:0), SM (18:1/16:0), 
SM (18:1/22:0) and GM2 (34:1) (Figure 1c). The lipid 
species that were located close to zero on the loadings 
plot had minimal capacity for differentiating between 
cells lines (Figure 1c). By comparing the loadings plot 
with the scores plot, it was evident that lipid profiles for 
LNCaP cells are dominated by PE (18:1/16:0), PC (32:1), 
PC (34:1), SM (18:1/20:0) and SM (18:1/16:0) (Figure 
1b, 1c). In 22RV1 cells, CE (18:1), PE (18:1/18:1), PC 
(36:2) and SM (18:1/22:0) were the dominant lipid 
species (Figure 1b, 1c). In DU145 cells, FC was the 
most abundant (Figure 1d) and the most dominant lipid 
species (Figure 1b, 1c). Of the lipids identified by PCA, 
PE (18:1/18:1) was the only lipid species that showed 
increased abundance across all three prostate cancer cell 
lines, when compared to PNT1a cells (Figure 1d). Direct 
comparison of each prostate cancer cell line with PNT1a 
is illustrated as a volcano plot (Supplementary Figure 1), 
which was generated based on the fold change (where 1 
indicates no change) and p value (p < 0.05) for a t-test of 
Figure 1: Quantitative LC-ESI-MS/MS data analysis of the relative abundances of lipids in prostate cell lines. (a) 
Comparison of average concentrations [nmol mg-1 protein] of (CE) cholesteryl esters, (SM) sphingomyelin, (FC) free cholesterol, (PE) 
phosphatidylethanolamine, (PC) phosphatidylcholine and (GM) gangliosides in prostate cell lines for six parallel samples with their standard 
error. One-way ANOVA and Tukey's multiple comparison tests showed significant differences among the means for the samples (depicted 
by different letters on the bars, p < 0.05). (b) The PCA scores plot comparing non-malignant PNT1a (black circles) and prostate cancer cell 
lines DU145 (green squares), 22RV1 (blue triangles) and LNCaP (red diamonds), using identified lipid species. (c) Loadings plot of PCA 
for PC-1 (equal to 78%). (d) Comparison of average concentrations [nmol mg-1 protein] of lipids that allowed the differentiation of non-
malignant PNT1a and prostate cancer cell lines, DU145, 22RV1 and LNCaP (p < 0.05). Data presented as mean ± SEM of six independent 
biological replicates for each of the four prostate cell lines.
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differences between PNT1a and prostate cancer cell lines 
(i. e., DU145, 22RV1 and LNCaP). This analysis also 
identified the 11 lipid species identified by PCA analysis 
to be significantly different between PNT1a and both 
22RV1 and LNCaP prostate cancer cell lines. In addition it 
showed a significant increase in the level of PE (18:1/18:0) 
in all three cancer cell lines compared to PNT1a and 
significant change in CE (18:1) for all three. Some of the 
less abundant lipid species, which were not identified as 
significant contributors to the separations in the PCA, 
where also identified by this approach when compared 
to PNT1a cells, for example, unsaturated CE species, 
CE (20:3) and CE (22:4) were at least twice as abundant 
in prostate cancer cells, when compared to PNT1a cells 
(Supplementary Figure 1, Supplementary Table 1). Thus, 
the abundance of specific SM and PC species, along with 
CE, may assist in differentiating prostate cancer cells. 
Significantly lipid profiles varied between prostate cancer 
cell lines, an observation which reflects the heterogeneous 
nature of this disease, but which may provide a useful tool 
for the phenotyping of prostate cancer.
To illustrate the lipid distribution and relative 
abundance within cells of these four cell lines, FTIR 
spectroscopy was used to map lipids in individual cells 
(Figure 2). The FTIR spectroscopy can recognise lipids to 
a class-level, does not require internal standards and can 
be applied to intact cells to generate a molecular image of 
the sample without the need for prior target identification 
[12, 14, 18]. The requirement of this technique is the 
use of samples of an appropriate thickness to allow a 
sufficiently large absorbance intensity to be recorded 
from the cell and to avoid recordings of spectra from the 
underlying substrate. Although the thickness of prostate 
cells varied making consistent sampling across individual 
cells difficult and resulting in low signal-to-noise ratio, 
an initial insight into the lipid biology of these cells was 
obtained using FTIR spectroscopy. Spectra were acquired 
over 3600–900 cm-1 range, where C–H (~3000–2800 cm-
1) and C=O (~1750–1700 cm-1) bands were located. The 
low signal to noise made mapping individual lipid groups 
within the cells difficult, however FTIR images of total 
lipid content were generated by integrating the area under 
the νs(CH2) band (2862–2847 cm
-1). This demonstrated 
that the lipids were not homogeneously distributed within 
the prostate cells; with the highest intensity observed 
in the perinuclear region and the lowest intensity at the 
cell periphery (Figure 2a/-2d/). Prostate cancer cell lines 
22RV1 and LNCaP cells had higher lipid concentrations 
(indicated by the higher intensity) and wider distribution 
of lipids, when compared to DU145 and PNT1a (Figure 
2a/-2d/) cells. Analysis of the FTIR spectra collected 
from prostate cancer cell lines confirmed the trend of 
increased intensity of lipid ν(CH) bands (Figure 2e, 2f). 
In addition, the position of the νas(CH2) and νs(CH2) bands 
shifted in the spectra of all three prostate cancer cells, 
when compared to PNT1a cells, which suggests altered 
lipid composition (Supplementary Table 2). PCA was also 
performed to interrogate two spectral regions (i. e. 3000–
2800 cm-1 and 1750–1700 cm-1; Figure 2g, 2h) containing 
lipid vibrational modes across the spectra collected from 
each cell line. In the scores plots (Supplementary Figure 
2a, 2c), PNT1a and prostate cancer cell lines, 22RV1 and 
LNCaP, had a better spatial separation along the PC-1 axis 
than with DU145 cells. Given the small sample size, the 
PCA analysis revealed poor separation of the cell lines 
on the plots. The PCA plot displayed positive loadings 
in the region of 2900–2880 cm-1 and 2840–2830 cm-1 
(Supplementary Figure 2b) associated with C-H stretching 
modes and the 1750–1734 cm-1 region (Supplementary 
Figure 2d) associated with the lipid ν(C=O) bands. 
Reference spectra, obtained for a range of pure lipid 
standards, indicated that peaks in the C-H stretching 
region were likely to be associated with FC or CE, while 
peaks in the C=O stretching corresponded with those of 
PE, PC and CE (Supplementary Table 3). These findings, 
in combination with the increase in the intensity of the 
ν(C-H) and ν(C=O) bands, indicate that prostate cancer 
cell lines exhibit altered lipid composition, which was 
detectable in individual cells and is in agreement with the 
LC-ESI-MS/MS findings on cell extracts.
To better determine lipi d localisation at a cellular 
level fluorescence microscopy was performed using 
a range of lipid localising dyes. Three commercially 
available lipid dyes were utilised, Filipin III was used 
for the visualisation of FC, BODIPY® 493/503 was 
selected for the detection of CE and TAG in lipid droplets 
and ReZolve-L1TM was chosen for its localisation with 
polar lipids, such as SM and PE [15, 19, 20]. Filipin III 
staining for FC revealed numerous intracellular vesicles 
in all four cells lines, with the brightest intracellular 
staining detected in LNCaP cells, followed by PNT1a 
cells (Figure 3a-3d). Cholesterol was detected in the 
region of the plasma membrane by Filipin III in PNT1a, 
LNCaP and 22RV1 cells and was particularly intense 
in 22RV1 cells (Figure 3a, 3c, 3d). In contrast, the 
fluorescent signal from Filipin III staining in DU145 
cells was minimal and restricted to the cytoplasm with no 
apparent plasma membrane staining. BODIPY® 493/503 
detected distinctive punctate structures throughout cells 
consistent with lipid droplets, where CE and TAG are 
known to reside. These compartments were distributed 
throughout the cytoplasm in PNT1a, DU145 and LNCaP 
cells (Figure 3e, 3g, 3h), but were accumulated in the 
cellular projections of 22RV1 cells (Figure 3g). BODIPY® 
493/503 detected many small lipid droplets in PNT1a 
cells (Figure 3e), while droplets in DU145 and LNCaP 
were comparatively large (Figure 3f, 3h). In the case of 
DU145 fewer (Figure 3f) lipid droplets were observed. 
In both 22RV1 and LNCaP cells, BODIPY® 493/503 was 
detected as diffuse cytosolic staining (Figure 3g, 3h), 
suggesting increased lipophilicity in the cytoplasm, which 
was not seen in the other two cell lines (Figure 3e, 3f). In 
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all three prostate cancer cell lines, polar lipid detection 
by ReZolve-L1TM detected small punctate structures, 
larger vesicular structures and extensive lipid networks 
throughout the cytosol, whereas in PNT1a cells ReZolve-
L1TM demonstrated only weak staining of punctate 
structures (Figure 3i-3l). The phosphorescence intensity 
from ReZolve-L1TM in PNT1a cells was only minimally 
above the detection threshold, which was in stark contrast 
to DU145, 22RV1 and LNCaP cells, which had intense 
emission patterns (Figure 3i-3l, Supplementary Figure 3e; 
p < 0.05). Quantification of emission intensity confirmed 
that DU145, LNCaP and 22RV1 cells had significantly 
Figure 2: FTIR spectroscopy on prostate cancer cells. (a-d) Optical and (a/-d/) FTIR images collected by integrating the area 
under the νs(CH2) band (2862–2847 cm
-1) and generated from (a, a/) PNT1a and prostate cancer cell lines, (b, b/) DU145, (c, c/) 22RV1 
and (d, d/) LNCaP. (e) Average FTIR spectra from PNT1a (black) and prostate cancer cell lines, DU145 (green), 22RV1 (blue) and LNCaP 
(red), acquired over the 3600–900 cm-1 spectral region, where (A) C–H and (B) C=O bands were located. (f) Averaged spectra of the C–H 
stretching region (3000–2800 cm-1) with band assignment. (g) Second-derivative spectra of the C–H stretching region shown in f. (h) 
Second-derivative spectra of the C=O stretching region.
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greater ReZolve-L1TM staining when compared to PNT1a 
cells (Supplementary Figure 3). This demonstrated that 
fluorescence imaging can be utilised to detect changes in 
lipid content and distribution within prostate cell lines, 
directly complementing the information obtained from 
LC-ESI-MS/MS and FTIR spectroscopy.
DISCUSSION
The heterogeneous nature of prostate cancer was 
reflected in the lipodomics analysis with significant 
variations reported between prostate cancer cells lines as 
well as between the non-malignant PNT1a cells and cancer 
cell lines. The key lipid classes identified in the AR-
positive cell lines, LNCaP and 22RV1, were overlapping 
with the three-lipid signatures (i.e. SM, ceramide and PC) 
found in metastatic castration-resistant prostate cancer 
plasma samples [11]. The AR-negative cell line, DU145, 
showed a significantly altered lipid profile in relation 
to PNT1a cells, and this relationship appeared to be the 
inverse of LNCaP and 22RV1 cells.
Differences observed in lipid profiles of prostate 
cells lines by LC-ESI-MS/MS, were also able to be 
detected at an individual cell level by FTIR spectroscopy 
and by fluorescent markers. However, both FTIR and 
fluorescence microscopy were limited in their resolution 
of lipid species and quantitative ability. Interestingly, 
the LC-ESI-MS/MS revealed elevated levels of FC 
in DU145 cells, but Filipin III staining of FC showed 
minimal visualisation in these cells. The increased 
staining of FC in LNCaP and 22RV1 cells, which 
was consistent with previous observations [21], did 
not match expected outcomes based on LC-ESI-MS/
MS results. Filipin III staining can be altered through 
cross-linking and mobilisation from aldehyde-based 
cell fixation methods [22]. In addition, Filipin III is 
known to display a nonlinear fluorescence response to 
FC abundance, which makes it unsuitable for accurate 
Figure 3: Distribution of lipids in prostate cancer cells. (a-l) Micrographs of cross-sections through prostate cells that show the 
intracellular location of neutral and polar lipids. Cholesterol was depicted by staining cells with Filipin III (a-d). Neutral lipids such as 
triglycerides and cholesteryl esters were detected by staining cells with BODIPY® 493/503 (e-h). ReZolve-L1TM (i-l) was used for staining 
polar lipids. Representative images from non-malignant PNT1a (a, e, i) and prostate cancer DU145 (b, f, j), 22RV1 (c, g, k) and LNCaP (d, 
h, l) cell lines. Prostate cells were fixed with 4% PFA (a-h) or imaged live (i-l). Scale bars, 20 μm.
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quantitation [23]. Like FC, accumulated CE has also 
been shown in prostate cancer cells [9], consistent with 
this neutral lipid accumulation detected by BODIPY® 
493/503 fluorescence; with increased cytoplasmic staining 
observed in 22RV1 and LNCaP cells and increased lipid 
droplet size in DU145 cells, when compared to PNT1a. 
Although the LC-ESI-MS/MS data indicated the highest 
abundance of CEs was in 22RV1 cells, DU145 and LNCaP 
cells both had significantly lower total CE than PNT1a. 
This was contrary to FTIR data, which indicated that 
LNCaP cells had only a slight reduction in the intensity 
of the band associated with ester groups, compared to 
22RV1 cells. This could relate to the localisation of lipid 
accumulation in 22RV1 cells as staining with BODIPY® 
493/503 showed lipid accumulation in the cell periphery 
where detection by FTIR was limited by sample thickness. 
Furthermore, using FTIR and BODIPY® 493/503 it is not 
possible to differentiate between CE and TAG therefore 
it is possible that the observed changes may relate to 
accumulation of other neutral lipids such as fatty acids 
and TAGs that have not been analysed in this study. These 
findings demonstrate a current limitation of fluorescence 
microscopy (due to the lack of availability of specific 
dyes) and FTIR, particularly for accurate assessment of 
cellular cholesterol species and demonstrate the need 
for careful consideration of the tools available when 
preforming lipid analysis.
Increased levels of all classes of phospholipids 
analysed were observed in prostate cancer cells compared 
to PNT1a using all analytical methods. Detailed analysis 
by LC-ESI-MS/MS analysis, found PE (18:1/18:1) was 
one of the few lipid species to be enriched in all three 
prostate cancer cell lines, when compared to PNT1a 
cells. Similarly, PE (18:1/18:1) has been detected in high 
abundance in exosomes derived from PC-3 cells [24] 
and in prostate cancer patient-derived plasma samples 
[8, 25]. Correspondingly, exosomes from patient urine 
have lipid signature characterised by increased PE, which 
were detected as ether-linked PE species [25]. Cellular 
PE can be converted to PC by phosphatidylethanolamine 
N-methyltransferase [26], and when compared to PNT1a, 
the PC content was increased in 22RV1 and LNCaP cells, 
but was reduced in DU145 cells. Two species of this lipid 
class, PC (32:1) and PC (36:2), were elevated in 22RV1 
and LNCaP prostate cancer cells. This observation was 
consistent with increases in these lipid species in other 
cancers [27–29] and with PC (34:1), which has also been 
reported to be increased in prostate cancer [8]. Differential 
abundance of saturated phospholipids, such as PE, PC and 
phosphatidylserine, markedly alter signal transduction 
and can protect cancer cells from oxidative stress-induced 
cell death [30, 31]. These phospholipids have been 
directly linked to cancer cell proliferation, involving Akt 
mediated signalling interactions between Raf-1 kinase 
inhibitory protein (RKIP) and PE [32], and the subsequent 
modulation of ROS production [33, 34].
Bioactive sphingolipids, such as ceramide and 
sphingosine, act as effector molecules in cell signalling 
and can regulate the response of prostate cancer cells to 
chemotherapy or radiation [35]. An increase in ceramides 
in cancer cells can be achieved through the hydrolysis 
of SM [35]. Similarly to PC, the amounts of SM were 
increased in 22RV1 and LNCaP cells, but not in DU145 
cells, when compared to PNT1a cells. The increased levels 
of SM (18:1/20:0) in 22RV1 and LNCaP may also relate 
to the altered release of exosomes from prostate cancer 
cells [36]. Similar to PC-3 prostate cancer cells [36], 
22RV1 and LNCaP displayed low amounts of GMs (e. g., 
GM2 (34:1)). Although GMs are potential biomarkers for 
lung [37] and breast [38] cancers, the exact species that 
contribute to cancer progression have yet to be identified. 
As sphingolipids are implicated in the regulation of 
steroidogenesis [39], the differential lipid profile observed 
in 22RV1 and LNCaP cells, compared with both DU145 
and PNT1a cells, may reflect their AR status. Androgens 
markedly influence the synthesis and uptake of fatty acids 
in prostate cells, and proteins involved in lipid metabolism 
may be influenced by differential modulation of the AR 
[40]. SM, ceramide and PC have been used as a three-
lipid signature to identify poor prognostic outcomes in 
castration-resistant prostate cancer [11]. This aligning 
of castration-resistant outcomes and the observations in 
cancer cells suggests that the identification of specific 
lipid signatures may aid in identifying novel biomarkers 
for prostate cancer.
The lipid profiles obtained from LC-ESI-MS/MS 
and FTIR spectroscopy were good predictors for the 
subsequent staining of polar lipids with ReZolve-L1TM. 
The LC-ESI-MS/MS analysis of prostate cancer 22RV1 
and LNCaP cells demonstrated elevated amounts of PE, 
PC and SM, which have previously demonstrated an 
association with ReZolve-L1TM [20]. These lipids have 
structural and functional consequences for cancer cell 
pathogenesis and disease progression. However, the 
correlation between intensity values of ReZolve-L1TM and 
levels of certain lipid classes are yet to be established. 
The visualisation of the altered polar lipids with ReZolve-
L1TM and apparently different patterns of lipid location 
within each of the prostate cancer cells suggested that 
lipid handling and metabolism may have the capacity to 
identify each of the cancer cell lines as a unique visual 
entity.
In summary, our work has provided further evidence 
of the role that lipids play in prostate disease, the need to 
carefully align cell choice when mapping in cellulo studies 
with those in tissue and to highlight the suitability of three 
analytical methods to the analysis of lipid profiles of cell 
models.
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MATERIALS AND METHODS
Cell lines and culture conditions
Human prostate non-malignant PNT1a and prostate 
cancer 22RV1, LNCaP (clone FCG) and DU145 cell 
lines were obtained from the European Collection of 
Cell Cultures via CellBank Australia (Children's Medical 
Research Institute, Westmead, NSW, Australia). PNT1a 
and 22RV1 cells were maintained in RPMI-1640 medium 
(#R0883, Sigma-Aldrich, USA), supplemented with 10% 
fetal bovine serum (#IVT3008403, In Vitro Technologies, 
Australia) and 2 mM L-glutamine (#25030-081, Gibco®, 
USA). LNCaP cells were maintained in RPMI-1640 
medium, supplemented with 2 mM L-glutamine, 10 
mM HEPES (#H0887, Sigma-Aldrich, USA) and 1 mM 
sodium pyruvate (#S8636, Sigma-Aldrich, USA). DU145 
cells were cultured in MEM medium (#M5650, Sigma-
Aldrich, USA), supplemented with 10% fetal bovine 
serum, 2 mM L-glutamine and 1 mM sodium pyruvate. 
The prostate cell lines were incubated at 37°C with 5% 
CO2 in a Sanyo MCO-17AI humidified incubator (Sanyo 
Electric Biomedical Co., Ltd.). Cells were passaged at 
approximately 80% confluence, for detachment TrypLE™ 
Express (#12604-021, Gibco®, USA) was used. The 
PNT1a cell line was chosen as a non-malignant control for 
comparison to three cancer cell lines, 22RV1, LNCaP and 
DU145. Prostate cancer lines 22RV1 and LNCaP closely 
mimic aspects of the more common clinical disease, as 
they are AR-responsive and express PSA [17]. On the 
other hand, DU145 represents a late-stage prostate cancer 
with moderate metastatic potential [16, 41], and is neither 
hormone-sensitive nor expresses PSA.
Lipid extraction and LC-ESI-MS/MS analysis
Prostate cell lines were seeded in 75 mm2 flasks 
(n = 6 for each cell line) at 1 x 105 cells mL−1. At ~80% 
confluence, cells were harvested and cell pellets were 
stored at -80°C until required for lysis. For lysis, each 
sample was resuspended in 200 μL of ice-cold lysis buffer 
(0.5 M NaCl / 0.02 M Tris / 0.1% NP-40, pH 7) and 
sonicated for a minute on ice at a power of 180 W at an 
amplitude of 20% in pulses of 10 seconds sonication / 10 
seconds of rest for each cycle (SONICA Q-500 Sonicator, 
Qsonica Llc., USA). For LC-ESI-MS/MS analysis, lipid 
extraction was achieved using the method of Folch, et al. 
[42]. Prior to extraction, samples were spiked with internal 
standards (40 pmol of C14 phosphatidylcholine (PC), 40 
pmol of C17 phosphatidylethanolamine (PE), 15.8 pmol 
of d35GM1 ganglioside and 11.2 nmol of d6-cholesterol). 
Analysis of free cholesterol (FC), cholesteryl esters (CE), 
PC, PE and gangliosides was performed using a Shimadzu 
LC-20AD binary pump system combined with a AB Sciex 
API 4000 Q-trap triple-quadrupole mass spectrometer 
equipped with Analyst software (Version 1.4.2) and a 
turbo-ionspray source. Liquid chromatography separation 
was achieved by injecting samples (20 μL) onto a 3 μm 
Alltima C18 column (50 x 2.1 mm) at 200 μL/min using 
the following conditions; the HPLC gradient program 
began with 70% mobile phase A (30% tetrahydrofuran / 
20% CH3OH / 50% 5 mM NH4COOH in H2O) followed 
by a linear ramp (0.01-7.0 min) to 100% mobile phase 
B (70% tetrahydrofuran / 20% CH3OH / 10% 5 mM 
NH4COOH in H2O) and maintained for 3 minutes. Re-
equilibration at 70% mobile phase A was performed for 
3 minutes prior to a subsequent injection. A Valco 10-
port post column valve diverted column flow to waste 
for the first 1.7 minutes. Analysis of FC, CE, PC and 
sphingomyelin was performed in positive-ion multiple 
reaction monitoring mode using an ion spray temperature 
of 200°C and voltage of 5000 V. Mass spectrometric 
analysis of PE and gangliosides was performed in 
negative-ion multiple reaction monitoring mode using an 
ion spray temperature of 200°C and voltage of -5000 V. 
Nitrogen was used as the collision gas at a pressure of 2 x 
10-5 Torr. Concentrations of each molecular species were 
calculated by relating the peak areas of each species to 
the peak area of the corresponding internal standard using 
Analyst 1.4.2 software.
The use of the N-acetylneuraminic acid fragment 
in the MRM pair for gangliosides negated the ability 
to differentiate the ceramide type, so we have denoted 
them with the total number of carbons and double bonds 
rather than two specified carbon chains. FC (and spiked 
d6-cholesterol internal standard) in each sample was 
converted to C2 cholesteryl ester by addition of 200 μL 
acetyl chloride/CHCl3 (1:5 v:v) and analysed by ESI-
MS/MS as described by Liebisch et al. [43]. Relative 
cholesterol levels were determined by relating the peak 
area of C2 cholesterol to the peak area of the C2 d6-
cholesterol internal standard. PC used the common product 
ion of m/z 184 corresponding to the phosphocholine head 
group and, therefore, PC species are denoted with the 
total number of carbons and double bonds rather than two 
specified carbon chains. The total protein level was used 
as loading control for the LC-ESI-MS/MS analysis, and 
the lipid content was presented as nmol mg-1 protein.
FTIR spectroscopy
For FTIR spectroscopy cells were seeded at a 
density of 1 × 105 cells mL-1 onto sterilised 2-mm thick 
CaF2 IR windows (Crystran, UK) using procedures 
developed previously for silicon nitride substrates [44]. 
After 24 hours fixed in 4% paraformaldehyde (PFA) for 30 
minutes at room temperature and then dipped three times 
in double-distilled water. Slides with prostate cells were 
left to dry on the benchtop for 24 hours.
FTIR spectra maps were collected using a Bruker 
Vertex 80v FTIR spectrometer coupled to a Hyperion 3000 
microscope, equipped with liquid-nitrogen-cooled 64 × 
64 Focal Plane Array (FPA) detector. Instrument control 
and data collection was carried out using OPUS software 
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(Version 7.0, Bruker, Ettlingen, Germany). Samples were 
continually purged with N2 to minimise water vapour and 
CO2 contributions in the spectral region 1350–1950 cm
-
1. FTIR images were collected using a ×36 microscope 
objective over the 3600–900 cm-1 spectral range with 
the co-addition of 1024 scans at a spectral resolution of 
4 cm-1 from two individual cells for each cell line (n = 
2). Analysis of a representative spectrum, generated from 
14–20 spectral data points selected from two images and 
averaged from each cell line. A background spectrum was 
acquired from a blank CaF2 window before the collection 
of each sample image.
FTIR spectra were analysed using OPUS software. 
False-colour functional group images were generated by 
measuring the area under specific regions of interest in 
both the original and second derivatives of the spectral 
data. Second derivative of the spectra were generated in 
OPUS using the Savitsky-Golay smoothing function. FTIR 
images were generated to illustrate the lipid distribution 
and relative abundance within each cell line by integrating 
the area under the νs(CH2) band (2862–2847 cm
−1; Figure 
2a/-2d/). The maximum intensity value of the FTIR image 
of 22RV1 cell had the highest integral intensity, therefore 
FTIR images from all cell lines were normalised against 
this value to allow direct comparison between the cell 
lines (Figure 2). For the selected spectral regions, PC-1 
accounted for by far the greatest contribution to the 
spectral differences (98% for 3000–2800 cm-1 and 81% 
for 1750–1700 cm-1), and therefore was chosen for further 
data interrogation (Supplementary Figure 2a, 2c).
Fluorescence imaging
For fluorescence imaging, prostate cells were seeded 
either at a density of 1 × 105 cells mL-1 on #1.5 coverslips 
(n = 3 for each cell line) or 1 × 104 cells mL-1 in 96-well 
plate (#CLS3603, Sigma-Aldrich, USA; n = 6 for each cell 
line), and were left to grow at 37°C with 5% CO2 for 24 
and 48 hours, respectfully. Prior to staining with BODIPY® 
493/503 (1:100, #D3922, Life Technologies, USA) 
and Filipin III (1:1000, #F9765, Sigma-Aldrich, USA), 
cells were fixed with 4% PFA. ReZolve-L1TM (Rezolve 
Scientific, Australia) staining was performed on live cells 
(Figure 3i-3l) and 4% PFA fixed cells (Supplementary 
Figure 3a-23). Results in live cells yielded similar results 
to staining in fixed cells (Figure 3, Supplementary Figure 
3); the intensity values of ReZolve-L1TM obtained in 
DU145, 22RV1 and LNCaP were higher than in PNT1a 
cells. Fixed cells were incubated with BODIPY® 493/503, 
Filipin III or ReZolve-L1TM for 30 minutes according to 
manufactures guidelines. Live cells were incubated with 
20 μM of ReZolve-L1TM in serum-free media for 30 
minutes at 37°C and 5% CO2. Following staining, the cells 
were washed with sterile PBS and mounted for imaging.
Images were acquired with a Ziess LSM710 
META NLO inverted microscope (Zeiss, Germany), 
which was supplemented with a two-photon Mai-Tai®, 
tunable Ti:Sapphire femtosecond pulse laser (710-920 
nm, Spectra-Physics, USA). All imaging experiments 
were carried out at room temperature. Imaging BODIPY® 
493/503 was performed using argon-gas solid-state 
laser (Zeiss, Germany). Filipin III was detected using 
two-photon excitation wavelength 720 nm, beam 
splitter MBS 690+ and emission interval 407-480 nm. 
ReZolve-L1TM fluorescence was acquired at 820 nm two-
photon excitation wavelength, beam splitter MBS 690+ 
and an emission interval of 493-601 nm. All images 
(n ≥ 10 for each cell line) were acquired using a Plan-
APOCHROMAT 63X/ NA1.4 oil immersion objective. 
Each confocal micrograph represented 1.0 μm thin optical 
sections.
Prostate cells grown in 96-well plate, fixed in 
4% PFA and stained with ReZolve-L1TM were imaged 
using Celldiscoverer 7 (Zeiss, Germany). ReZolve-L1TM 
fluorescence was acquired by utilising LED 385, with 
emission collected at 583-601 nm. Light source intensity 
was set to 10%, the depth of focus was 1.90 μm and the 
exposure time was 500 ms. For label-free imaging of 
cells, phase gradient contrast was employed. The number 
of images collected for each cell line was 30, and all of 
them were acquired using a Plan-APOCHROMAT 20X/ 
0.7 dry objective.
Statistical analysis
All data are presented as means ± s.e.m. Quantitative 
measurements of intensity values of ReZolve-L1TM 
staining in prostate cancer cell lines were made on digital 
images (n ≥ 10 for each cell line), using ZEN software 
(blue addition; Zeiss, Germany). The intensity value 
from each digital image (n ≥ 10) was plotted in GraphPad 
Prism (version 7 for Windows, GraphPad Software, San 
Diego, CA USA) for each designated group (PNT1a, 
DU145, 22RV1 and LNCaP). The statistically significant 
differences between group means were evaluated by one-
way analysis of variance (ANOVA), with individual group 
variance assessed by a Bartlett's test. Where the level of 
significance was p < 0.05, post-hoc tests were performed 
using a Tukey's multiple comparison test. The fold change 
between PNT1a and cancer cell lines was obtained from 
the mean values (n = 6 for each lipid specie). Student’s 
t-test was used to assess the differences between PNT1a 
and prostate cell lines (i. e., DU145, 22RV1 and LNCaP) 
for the generation of the ‘volcano plot’. GraphPad Prism 
was used for all statistical analyses.
Principal component analysis (PCA) was performed 
using Unscrambler software (Version 9.7, CAMO, Olson, 
Norway). The multivariate statistical analysis method used 
in PCA allowed the data to be visualised in a reduced-
dimension space, with each sample being converted into 
a single score [45]. PCA scores and loadings plots were 
obtained from the raw data. The score groups were plotted 
using selected principal components (PCs) as coordinates, 
with scores spatially separated based on sample 
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similarity. The Hotelling’s T2 test, which corresponded 
to a multivariate generalisation of the 95% confidence 
interval, was utilised to identify outliers in the LC-ESI-
MS/MS dataset.
Image processing
Representative images and graphs were collated 
using Adobe Photoshop CC (Adobe Systems Inc, USA).
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